Bio-Techne (TECH) Total Current Liabilities (2010 - 2026)
Bio-Techne (TECH) posted quarterly Total Current Liabilities of $153.3 million for Q1 2026, down 9.41% year-over-year from $169.2 million in Q1 2025, and up 9.15% quarter-over-quarter from $140.4 million in Q4 2025.
Bio-Techne (TECH) Total Current Liabilities (2010 - 2026) Analysis & Trends
Bio-Techne's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $153.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 9.41% year-over-year to $153.3 million; the TTM figure through Mar 2026 stood at $153.3 million (down 9.41% YoY), while the FY2025 annual figure was $175.8 million, up 10.33% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $153.3 million, up from $140.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $176.0 million in Q2 2022, with the low at $127.8 million in Q3 2023.
- The 5-year median for Total Current Liabilities is $144.5 million (2025), against an average of $149.3 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities dropped 26.99% in 2023, then rose 24.02% in 2024.
- Bio-Techne's Total Current Liabilities stood at $128.4 million in 2022, then rose by 5.32% to $135.2 million in 2023, then grew by 19.24% to $161.3 million in 2024, then fell by 12.92% to $140.4 million in 2025, then gained by 9.15% to $153.3 million in 2026.
- Business Quant data shows TECH's Total Current Liabilities at $153.3 million in Q1 2026, $140.4 million in Q4 2025, and $144.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 153.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.28 Mn |
| Dec 31, 2025 | 140.43 Mn |
| Sep 30, 2025 | 144.55 Mn |
| Jun 30, 2025 | 175.85 Mn |
| Mar 31, 2025 | 169.20 Mn |
| Dec 31, 2024 | 161.26 Mn |
| Sep 30, 2024 | 142.13 Mn |
| Jun 30, 2024 | 159.38 Mn |
| Mar 31, 2024 | 149.82 Mn |
| Dec 31, 2023 | 135.23 Mn |
| Sep 30, 2023 | 127.75 Mn |
| Jun 30, 2023 | 128.51 Mn |
| Mar 31, 2023 | 141.16 Mn |
| Dec 31, 2022 | 128.40 Mn |
| Sep 30, 2022 | 137.63 Mn |
| Jun 30, 2022 | 176.02 Mn |
| Mar 31, 2022 | 166.84 Mn |
| Dec 31, 2021 | 154.81 Mn |
| Sep 30, 2021 | 133.99 Mn |
| Jun 30, 2021 | 152.28 Mn |